Johnson & Johnson Free Cash Flow 2010-2024 | JNJ
Johnson & Johnson annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Johnson & Johnson free cash flow for the quarter ending September 30, 2024 was 15,094.00, a year-over-year.
- Johnson & Johnson free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.
- Johnson & Johnson annual free cash flow for 2023 was $18.606B, a 4.95% increase from 2022.
- Johnson & Johnson annual free cash flow for 2022 was $17.728B, a 13.39% decline from 2021.
- Johnson & Johnson annual free cash flow for 2021 was $20.469B, a 0.12% decline from 2020.
| Johnson & Johnson Annual Free Cash Flow |
| 2023 |
18,606.00 |
| 2022 |
17,728.00 |
| 2021 |
20,469.00 |
| 2020 |
20,494.00 |
| 2019 |
23,183.00 |
| 2018 |
21,734.00 |
| 2017 |
19,609.00 |
| 2016 |
16,808.00 |
| 2015 |
19,570.00 |
| 2014 |
19,627.00 |
| 2013 |
14,277.00 |
| 2012 |
13,971.00 |
| 2011 |
12,747.00 |
| 2010 |
14,525.00 |
| 2009 |
14,360.00 |
| Johnson & Johnson Quarterly Free Cash Flow |
| 2024-09-30 |
15,094.00 |
| 2024-06-30 |
8,080.00 |
| 2024-03-31 |
3,060.00 |
| 2023-12-31 |
18,606.00 |
| 2023-09-30 |
12,211.00 |
| 2023-06-30 |
5,568.00 |
| 2023-03-31 |
2,434.00 |
| 2022-12-31 |
17,728.00 |
| 2022-09-30 |
13,744.00 |
| 2022-06-30 |
8,404.00 |
| 2022-03-31 |
3,620.00 |
| 2021-12-31 |
20,469.00 |
| 2021-09-30 |
16,107.00 |
| 2021-06-30 |
8,552.00 |
| 2021-03-31 |
4,000.00 |
| 2020-12-31 |
20,494.00 |
| 2020-09-30 |
13,269.00 |
| 2020-06-30 |
5,610.00 |
| 2020-03-31 |
2,750.00 |
| 2019-12-31 |
23,183.00 |
| 2019-09-30 |
17,883.00 |
| 2019-06-30 |
11,016.00 |
| 2019-03-31 |
3,140.00 |
| 2018-12-31 |
21,734.00 |
| 2018-09-30 |
14,500.00 |
| 2018-06-30 |
9,022.00 |
| 2018-03-31 |
2,968.00 |
| 2017-12-31 |
19,609.00 |
| 2017-09-30 |
13,638.00 |
| 2017-06-30 |
7,561.00 |
| 2017-03-31 |
2,384.00 |
| 2016-12-31 |
16,808.00 |
| 2016-09-30 |
10,854.00 |
| 2016-06-30 |
6,042.00 |
| 2016-03-31 |
1,575.00 |
| 2015-12-31 |
19,570.00 |
| 2015-09-30 |
14,007.00 |
| 2015-06-30 |
8,229.00 |
| 2015-03-31 |
2,439.00 |
| 2014-12-31 |
19,627.00 |
| 2014-09-30 |
16,369.00 |
| 2014-06-30 |
8,558.00 |
| 2014-03-31 |
3,328.00 |
| 2013-12-31 |
14,277.00 |
| 2013-09-30 |
11,301.00 |
| 2013-06-30 |
6,118.00 |
| 2013-03-31 |
1,797.00 |
| 2012-12-31 |
13,971.00 |
| 2012-09-30 |
11,143.00 |
| 2012-06-30 |
6,630.00 |
| 2012-03-31 |
2,651.00 |
| 2011-12-31 |
12,747.00 |
| 2011-09-30 |
9,803.00 |
| 2011-06-30 |
5,314.00 |
| 2011-03-31 |
2,001.00 |
| 2010-12-31 |
14,525.00 |
| 2010-09-30 |
11,460.00 |
| 2010-06-30 |
6,739.00 |
| 2010-03-31 |
3,395.00 |
| 2009-12-31 |
14,360.00 |
| 2009-09-30 |
9,775.00 |
| 2009-06-30 |
5,200.00 |
| 2009-03-31 |
2,398.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$342.027B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
